Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trotabresib in advanced solid tumors and NHL
NCT03220347Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Jul 2017
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of trotabresib in solid tumor, non-Hodgkin lymphoma (NHL), basal cell carcinoma (BCC) and 3 more, sponsored by Celgene Corporation. Primary endpoints: Adverse Events up to 7 years, Dose Limiting Toxicities up to 7 years and 1 more. Started Jul 2017; status: terminated.
02
Drugs
trotabresib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)basal cell carcinoma (BCC)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03220347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220347.